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Abstract
Sepsis, defined as an infection with dysregulated host response leading to life-
threatening organ dysfunction, continues to carry a high potential for morbidity
and mortality in children. The recognition of sepsis in children in the emergency
department (ED) can be challenging, related to the high prevalence of common febrile
infections, poor specificity of discriminating features, and the capacity of children
to compensate until advanced stages of shock. Sepsis outcomes are strongly depen-
dent on the timeliness of recognition and treatment, which has led to the successful
implementation of quality improvement programs, increasing the reliability of sepsis
treatment inmanyUS institutions.We review clinical, laboratory, and technical modal-
ities that can be incorporated into ED practice to facilitate the recognition, treatment,
and reassessment of children with suspected sepsis. The 2020 updated pediatric sep-
sis guidelines are reviewed and framed in the context of ED interventions, including
guidelines for antibiotic administration, fluid resuscitation, and the use of vasoactive
agents. Despite a large body of literature on pediatric sepsis epidemiology in recent
years, the evidence base for treatment andmanagement components remains limited,
implying an urgent need for large trials in this field. In conclusion, although the burden
and impact of pediatric sepsis remains substantial, progress in our understanding of
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the disease and its management have led to revised guidelines and the available data
emphasizes the importance of local quality improvement programs.
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severe sepsis
1 INTRODUCTION AND EPIDEMIOLOGY
Sepsis contributes to 19% of all deaths globally, with the highest age-
specific incidence in children younger than 5 years of age.1,2 Pediatric
sepsis resulted in 0.7% of all hospital encounters, with an incidence of
2.8% in inpatients in the United States.3 Epidemiologic studies using
clinical data have found an incidence of pediatric sepsis in up to 8% of
all pediatric intensive care unit (PICU) admissions,4 contributing to 1
in 4 deaths in PICUs.5 Accurate estimates of pediatric sepsis are ham-
pered by inaccuracies of diagnostic coding, resulting in gross under-
reporting; at the same time, increasing sepsis awareness may lead to
identification earlier in the disease process, with resultant increases
in apparent survival rates.6 To address this, novel sepsis surveil-
lance criteria derived from electronic health record data have been
proposed.7,8
Risk factors for sepsis and the most common sites and pathogens
associated with sepsis are described in Tables 19–11 and 2,3,10,11
respectively. In 1 US multicenter study, the most common pathogens
affecting previously healthy children were Staphylococcus aureus
(9.4%), streptococcal species (7.9%), and Escherichia coli (7.1%),
whereas themost commonpathogens in childrenwith chronic diseases
were S. aureus (11%), Candida (9.8%), and Pseudomonas (8.1%).12 Simi-
lar patterns have been observed in recent population-based studies in
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Respiratory (including ventilator dependence) 5–7
Congenital or acquired immune deficiency 4–7
Renal 2–6
Gastrointestinal 4–5
Solid organ transplant 4
Dialysis dependence 3
Bonemarrow transplantation 3
aSum >100% as ranges compiled from various studies and patients may
have hadmultiple comorbidities.
other countries and contrast with the predominance of meningococ-
cal infections observed in previous decades.5,13 More than one-third
of children with sepsis do not have an identifiable pathogen. This may
be attributed to sepsis being caused by viral etiologies or because of
the limits in detection of bacterial pathogens, particularly if the vol-
ume inoculated into blood cultures is low or if the pathogens are fas-
tidious or have specific growth requirements. Table 3 summarizes the
most common pathogens by site of infection in non-resource-limited
settings.12
2 DEFINITIONS
Historically, the term sepsis (from Greek “sepsin,” meaning “rot, make
putrid”) has been used to characterize life-threatening infections usu-
ally caused by bacterial pathogens if untreated progress to shock
and death.14 The 2005 International Pediatric Sepsis Definition Con-
sensus Conference classified sepsis as infection in presence of sys-
temic inflammatory response syndrome (SIRS), severe sepsis as sep-
sis in the presence of organ dysfunction, and septic shock as sep-
sis in the presence of cardiovascular dysfunction (Table 4).15–17
Although SIRS criteria have been used in many EDs to assist in the


















aSum >100% as ranges compiled from various studies and patients may
have hadmultiple sites of infections or polymicrobial infections.
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TABLE 3 Most common pathogens by site of infection in childrenwith sepsis
Organism Bacteremia (%) CNS (%) UTI (%) SSTI (%) Pneumonia (%) Osteomyelitis (%)
S. aureus 19 12 6 30 15 51
S. pneumoniae 2 9 1 0.2 4 1
Other Gram-positives 28 25 9 11 6 16
K. pneumoniae 8 2 5 1 3 2
E. coli 11 2 23 2 5 3
H. influenzae 1 3 0.3 0.4 4 1
Pseudomonas 7 2 5 4 13 3
Other Gram-negatives 13 9 6 3 10 2
Candida 9 9 5 7 7 5
Aspergillus 0.4 1 0.2 0.5 0.3 0
No identifiable pathogen N/A 21 36 37 31 15
Note. Adapted from Prout et al.9,12
Abbreviations: CNS, central nervous system; N/A, not applicable; SSTI, skin/soft tissue infection; UTI, urinary tract infection.
TABLE 4 Approaches to defining sepsis in children
Term Term Definition
2005 International Pediatric Sepsis
Definition Consensus conference
SIRS Meets≥2 of the following criteria, 1 of whichmust be temperature orWBC
count:
Pyrexia (>38.5◦C) or hypothermia (<36◦C)
Age-dependent tachycardia or bradycardia
Tachypnea or need for mechanical ventilation
AbnormalWBC count or>10% bands
Sepsis SIRS and
Suspected or confirmed infection
Severe sepsis Sepsis and
Cardiovascular dysfunction, respiratory dysfunction, or≥2
non-cardiorespiratory organ system dysfunctions
Septic shock Sepsis and
Cardiovascular dysfunction: defined as either hypotension, receipt of
vasoactivemedication, or impaired perfusion despite fluid resuscitation
Sepsis-3 (adults) Sepsis Suspected or confirmed infection and
Presence of organ dysfunction (measured by SOFA score or qSOFA score
increase in≥2 points)
Septic shock Suspected or confirmed infection and
Cardiovascular dysfunction defined as hypotension despite fluid resuscitation
requiring vasoactivemedication in presence of hyperlactatemia
Operationalization for the 2020 Pediatric
surviving sepsis campaign
Sepsis Suspected or confirmed infection and
Sepsis-associated organ dysfunction or septic shock
Note. Adapted fromGoldstein et al,15 Shankar-Hari et al,16 andWeiss et al.17
Abbreviations: qSOFA, quick SOFA; SIRS, systemic inflammatory response syndrome; SOFA, sequential organ failure assessment.
recognition of children who may have sepsis, SIRS vital sign criteria
are poorly sensitive in identifying critically ill children.18,19 Recently,
definitions of sepsis in adults have changed, with the 2016 Sepsis-3
consensus conference defining sepsis as infection with dysregulated
host response resulting in life-threatening organ dysfunction and sep-
tic shock as sepsis with profound circulatory, cellular, or metabolic
alterations associated with substantially higher mortality.16 There is
a requirement of hypotension to meet adult shock criteria, contrary
to the pediatric goal of identifying compensated shock, given that
hypotension is a late-stage finding for children. We refer to sep-
sis as sepsis-associated organ dysfunction and septic shock as sep-
sis with cardiovascular dysfunction (including hypotension, need for
treatment with vasoactive agents, or impaired perfusion)17 in this
review.
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3 SEPSIS BUNDLES AND QUALITY
IMPROVEMENT INITIATIVES
Failure to recognize sepsis increases the risk of morbidity and mor-
tality, as illustrated by the case of Rory Staunton, a 12-year-old boy
who died of initially unrecognized streptococcal sepsis.20 A year after
Rory’s death, “Rory’s Regulations” were passed,21 requiring all New
York hospitals to implement evidence-based protocols to facilitate
early recognition of sepsis through screening tools, identify individu-
als who qualified for sepsis care, and implement guidelines for sepsis
management through bundled care, consisting of protocols to assist in
sepsis recognition and subsequently prompt initiation of fluid resus-
citation, parenteral antibiotics, and obtaining blood cultures. Multiple
studies demonstrated an improvement in in-hospital mortality rates
after bundled sepsis care in both children22 and adults.23 In addi-
tion to legislative efforts, US children’s hospitals have collaborated to
enhancemulticenter quality improvement activities in pediatric sepsis.
The largest of these efforts is the ongoing Improving Pediatric Sepsis
Outcomes Collaborative through the Children’s Hospital Association
and involves>50 hospitals across the United States.24
The benefits of early recognition, treatment, and reversal of
shock using bundled sepsis care extend beyond reductions in
mortality.22,23,25 Multiple pediatric studies have demonstrated
decreased hospital length of stay after implementation of bundled
care26,27 and reductions in the rates of acute kidney injury.28 Delays
in receipt of antimicrobial therapy are associated with increased
mortality, with children who experienced antibiotic delays of more
than 3 hours having an almost 4-fold risk of mortality in the PICU.29
Other studies have found that each additional hour of persistent
shock is associated with a >2-fold increased odds of mortality.30
Ultimately, many pediatric studies have evaluated the relationship
between the timing of antibiotic administration and fluid resuscitation
through protocol-driven care and patient-level outcomes,22,25–28
driving ongoing revisions to institutional, national, and international
guidelines.
4 DIAGNOSIS
Early diagnosis is critical to reversing shock. Barriers to recognition
include age-related variation in vital signs (resulting in failure to rec-
ognize abnormal vital signs), hypotension being a late manifestation,
a relatively low prevalence of pediatric sepsis in EDs in high-income
countries, and alternative explanations for abnormal vital signs (fever
or crying contributing to tachycardia or tachypnea). There are also
associated challenges in identifying which children meeting SIRS
criteria may be at risk for sepsis. As such, we review triage-based and
laboratory-based tools that may optimize sepsis recognition.
4.1 Triage-based recognition
Rapid, systematic identification of children with sepsis is paramount
to initiating timely interventions. Without this critical step, delays in
care may impact morbidity and mortality. In 2017, the American Col-
legeofCriticalCareMedicine (ACCCM)onPediatric andNeonatal Sep-
tic Shock emphasized the importance of triggers or screening tools to
rapidly identify patientswith septic shock.31 In 2020, the first Pediatric
Surviving Sepsis Campaign (SSC) international guidelines extended the
goal of identification to non-cardiovascular dysfunction.17
The clinical signs of those at risk for pediatric sepsis are largely
based on the presence of suspected infection and abnormal physical
examination findings such as perfusion abnormalities, altered men-
tal status, hypotension, temperature abnormality (fever or hypother-
mia), and tachycardia.31,32 A pragmatic screen/alert should be based
on these readily identifiable and available parameters. Incorporating
a sepsis screen into the triage process is efficient and identifies most
patients with sepsis.25 In 1 ED study, moving from a paper-based to
an electronic health record process significantly decreased time to
recognition.33
The significant mortality and morbidity associated with pediatric
sepsis drives the inherent balance of sensitivity versus specificity of all
screeningmodels to favor sensitivity at the cost of specificity.However,
this results in a low positive predictive value, and balancing measures
related to false positive alerts and the potential for alert fatigue need
to be considered. Design should consider institution-specific charac-
teristics (ie, tertiary/quaternary vs rural or community setting, acu-
ity, healthcare workers awareness/sensitivity to sepsis)17,34 and can
include temperature-corrected heart and/or respiratory rate,35,36 age-
based vital sign adjustments,33,36–39 and the inclusion of high-risk
conditions.25,33,37
Some of the earliest adopters of sepsis screening in pediatric EDs
primarily leveraged vital sign abnormalities to identify patients with
possible sepsis (Table 5).35–40 An ideal pediatric sepsis screening pro-
cess should be efficient, initiated at first contactwith the patient, incor-
porate reassessment/identification throughout the visit, and harness
the strength of the electronic health record. The screen should incor-
porate pertinent vital sign and clinical parameters, recognize children
with high-risk conditions, involve a care team huddle/bedside assess-
ment, and be monitored by a dedicated quality improvement team.
Because clinician assessment can significantly improve screening per-
formance, a 2-step process consisting of a screening tool prompting
timely medical evaluation has the potential to combine the advan-
tages in terms of the sensitivity and specificity of both steps.37,41 Per-
forming a 2-step screening process is well aligned with other care
processes in the ED setting and is effective.25,37 The first step is
nurse driven, involves responding to an electronic alert determined
by the presence of abnormal vital signs and/or clinical parameters,
and takes into consideration the presence of high-risk conditions. If
the screen is positive, a bedside care team huddle is performed to
assess the patient and determine if sepsis pathway management is
appropriate.
Successful implementation and subsequent administration of a
pediatric sepsis screening process is a large quality improvement
effort requiring a dedicated and engaged workgroup. Screening
pathways require adherence and performance monitoring with
modifications to improve compliance and optimize sensitivity and
specificity.
CRUZ ET AL. 985



















Cruz et al (2012)35 + +, internally derived + + + 81 4
Sepanski et al (2014)36 + +, modified SIRS + − + 97 49
Lane et al (2016)25 + −, modified PALS + + + 99 20
Balamuth et al (2017)37 + +, modified PEWS + + + 86 25
Lloyd et al (2018)33 + +, modified PALS + + + NR NR
Powell et al (2018)40 − −, PEWS + + + NR NR
Note.−, heart rate not adjusted for pyrexia;+, heart rate adjusted for pyrexia.
Abbreviations: EHR, electronic health record; NR, not reported; PALS, pediatric advanced life support; PEWS, pediatric early warning signs; PPV, positive
predictive value; SIRS, systemic inflammatory response syndrome.
4.2 Laboratory-based diagnostics
AWBC count≥15,000 cells/µL was historically used to identify febrile
young children at higher risk of occult bacteremia.42 However, stud-
ies conducted in the post–pneumococcal conjugate vaccine era have
demonstrated thatWBC count has poor test characteristics for bacte-
rial infections across age groups and that no single cut-off value has a
sufficient sensitivity or specificity for clinical utility.43–46 Although ele-
vated absolute band count >1500 cells/µL has high specificity (>90%)
for bacterial infections, the sensitivity is very low (<30%).45,47 Sim-
ilarly, an absolute neutrophil count >10,000 cells/µL has moderate
to high specificity (78%–88%) but poor sensitivity (<50%) for bac-
terial infection when used in isolation.44–46 The absolute neutrophil
count is part of the step-by-step approach and Pediatric Emergency
Care Applied Research Network (PECARN) prediction rule to iden-
tify febrile infants ≤60 days of age at low risk of bacterial infections
(Table 6).48,49
C-reactive protein is often integrated into identification of febrile
infants with bacterial infections. A C-reactive protein cut-off of
2 mg/dL has moderate sensitivity (88%) and specificity (60%) for iden-
tification of febrile children with bacterial infections, with higher lev-
els (eg,>8mg/dL) having higher specificity.50 Other studies have found
lower diagnostic utility for C-reactive protein used in isolation to iden-
tify septic children.51,52 Yet all of these laboratory parameters have low
positive predictive value for predicting sepsis.
Procalcitonin (PCT) has the most favorable test characteristics
for the identification of children with bacterial infections, particu-
larly for invasive bacterial infection (IBI) (bacteremia and/or bacte-
rial meningitis).45,53 Among febrile infants ≤60 days of age, a PCT
level of <0.5 ng/mL should be used in combination with other clin-
ical and laboratory parameters to identify infants at low risk of IBI
(Table 6).48,49 For febrile older children, a PCT level of >0.5 ng/mL
has low sensitivity (55%) and moderate specificity (85%) for bacte-
rial infections, although its sensitivity is higher for IBI (82%).53 A PCT
level of >2 ng/mL has low sensitivity (61%) for IBI but high specificity
(94%) and can be used to identify febrile children at higher risk of
sepsis.53 PCT use in adults with suspected sepsis has demonstrated
TABLE 6 Step-by-step approach and PECARN prediction rule for
identification of well-appearing febrile infants with bacterial
infections
Step-by-step approach PECARN prediction rule
Age range ≤90 days ≤60 days
History No source of fever Gestational age≥36weeks

















Low risk None of the above
present

















Note. Adapted from Gomez et al48 and Kuppermann et al.49 The majority
of patients with bacterial infections in these studies did not have organ dys-
function.
Abbreviations: ANC, absolute neutrophil count; CI, confidence interval;
CRP, C-reactive protein; PCT, procalcitonin; PECARN: pediatric emergency
care applied research network.
aRoit iunded cut-off values.
bSensitivity and specificity calculated using data from the validation study.
cSensitivity and specificity calculated from combined derivation and valida-
tion data using rounded cut-off values.
mixed results.54,55 Further data are needed on the role of PCT in chil-
dren with suspected sepsis. A major limitation of currently available
evidence relates to the fact that serious bacterial infection rather than
sepsis, or infectionwith organ dysfunction, was used as the outcome in
diagnostic accuracy studies.
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Serum lactate>2mmol/L (>18mg/dL) is a component of the Sepsis-
3 definition of septic shock in adults.16 Studies have reported that
increasing lactate levels, both venous and arterial,56 are associated
with a higher risk of organ dysfunction and mortality in children with
infection, in particular if >4 mmol/L (>36 mg/dL).57,58 Although a nor-
mal lactate does not exclude a sepsis diagnosis in children, high levels
should raise suspicion for sepsis and septic shock in the appropriate
clinical context and prompt aggressive resuscitation.31
4.3 Novel biomarkers and sepsis phenotypes
The complexity of pediatric sepsis makes it unlikely that any sin-
gle biomarker in isolation will have sufficient diagnostic or prog-
nostic capability. Consequently, most successful strategies in sepsis
biomarker development have taken a multimarker approach. Because
sepsis pathophysiology can affect multiple organ systems, particular
interest has been paid to mechanisms spanning organ systems includ-
ing immune, vascular, and bioenergetic dysfunction.
Novel biomarkers can define pediatric sepsis endotypes. Wong et
al59 identified 5markers for the Pediatric Sepsis Biomarker RiskModel
(PERSEVERE) biomarker risk model: C-C chemokine ligand 3 (CCL3),
interleukin 8 (IL8), heat shock protein 70 kDa 1B (HSPA1B), granzyme
B (GZMB), and matrix metallopeptidase 8 (MMP8). These markers in
combination were associated with 28-day mortality. Addition of the
platelet count (PERSEVERE II)60 and elements of the tumor protein 53
pathway (PERSEVERE-XP) allowed more precise prediction of 28-day
mortality.61Wonget al62 identified higher pathogenburden in children
with higher PERSEVERE II scores. One important caveat is that this
work focused on children in the ICU with established sepsis diagnoses
who were already severely ill at time of biomarker assessment. The
performance of PERSEVERE or similar ICU-based markers in a more
undifferentiated population of childrenwith possible sepsis, where the
aim is to identify those about to deteriorate, remains unknown.
RNA expression profiling also has been proposed as a tool to distin-
guish pathogen type in children. Blood cultures lack sensitivity (false
negatives with sporadic bacteremia or low blood culture volumes) and
specificity (contaminants) and are slow to result. A large multicenter
study identified gene expression patterns associated with bacterial
versus viral infection in febrile young infants,63 and others have iden-
tified candidatemarkers in older children as well.64–66
5 ED MANAGEMENT: THE 2020 PEDIATRIC SSC
GUIDELINES
In February2020, theSSCpublished thenewguidelines (Figure1)17 for
the management of children with sepsis. Of the 77 statements, 6 were
strong recommendations and 9 were best practice statements (BPS)
(Table 7).17 For most of the guidelines, there were inadequate data to
make strong recommendations in support of or against various inter-
ventions, reflecting the paucity of randomized trials in the field of pedi-
atric sepsis. The guidelines are based on systematic literature review
followed by rigorous evaluation of the evidence and discussion in the
expert panel to provide guidance for most scenarios relevant to ED
management.
5.1 General management
The guidelines emphasize the role of systematic screening for sep-
sis while acknowledging that there is no best screening/recognition
tool and that implementation of screening procedures requires care-
ful consideration of the local epidemiology and processes, with regu-
lar calibration and evaluation. Building on a body of retrospective and
prospective observational studies that report on improved outcomes
related to timely protocolized treatment, the new guidelines recom-
mend the implementation of institutional protocols for the manage-
ment of sepsis. Sepsis bundles should consist of the following 6 steps:
obtain intravenous/intraosseous infusion access, collect blood cultures
and lactate, initiate of empiric broad-spectrumantibiotics early, admin-
ister fluid bolus if shock is present, and consider vasoactive agents if
shock persists.
5.2 Antibiotic management
Empiric antibiotic therapy should be initiated as quickly as possible for
children with sepsis. Empiric broad spectrum parenteral agents should
be administered based on the child’s age, presenting features/focus
of infection, comorbidities such as immunocompromise, and local
epidemiology in relation to disease prevalence and antimicrobial
resistance patterns. One approach for empiric antibiotics based on the
presumed site of infection and a child’s comorbid medical conditions is
described in Table 8.17,67–69
Antibiotics should be administered as soon as possible, ideally
within an hour of the recognition of septic shock.17 This recommen-
dation is based on the observational data demonstrating improved
survival associated with early antibiotics in cohorts of children with
a predominance of septic shock.22,29,70,71 Antibiotic administration
should follow blood culture sampling, but not be delayed while await-
ing the collection or results of diagnostic testing, including lumbar
puncture, in children with shock. In practice, however, many children
presenting to EDs being evaluated for sepsis are not in shock, and sep-
sismay represent one of several diagnostic options. In childrenwithout
shock, the SSC panel considered the benefits of rapid antibiotic admin-
istrationwithbalancingmeasures related to theexposureof non-septic
children to potentially unnecessary antibiotics.72 In children with sep-
sis without shock, the 2020 SSC recommends starting antimicrobial
therapy after appropriate evaluation andwithin 3 hours of recognition.
5.3 Initial fluid and inotrope resuscitation,
and hemodynamic monitoring
Although intravenous fluid boluses remain a cornerstone of the
resuscitation of children with septic shock, an increasing number of
publications have highlighted the increased morbidity and mortal-
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F IGURE 1 Surviving Sepsis Campaign algorithm for the initial resuscitation of children with suspected sepsis. Usedwith permission from the
Surviving Sepsis Campaign. ECLS, extracorporeal life support; IO, intraosseous infusion; IV, intravenous; VA, veno-arterial; VV, veno-venous
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TABLE 7 Surviving Sepsis Campaign international guidelines for the initial management of pediatric septic shock and sepsis-associated organ
dysfunction: strong recommendations and best practice statements applicable to the emergency department setting
Category Recommendation
Recognition Implement systematic screening for timely recognition of septic shock and other sepsis-associated organ dysfunction
a
Implement a protocol for management of sepsis-related organ dysfunction (BPS)
Obtain blood cultures before starting antimicrobial therapy if this does not delay antimicrobial administration (BPS)
Antimicrobial therapy and
antimicrobial stewardship
Administer antibiotics within 1 hour of recognition to childrenwith septic shock andwithin 3 hours of recognition in
childrenwith sepsis-associated organ dysfunction without shock
Start with empiric broad-spectrum antibiotics to cover all likely pathogens (BPS)
Narrow antimicrobial coverage after culture and susceptibility data are available (BPS)
Narrow coverage or discontinue antimicrobials if no pathogen is identified, considering site of infection, clinical
improvement, and patient risk factors (BPS)
Optimize antimicrobial drug dosing based on pharmacokinetic data (BPS)
Reassess daily for antimicrobial de-escalation (BPS)
Determine antimicrobial duration based on site of infection, etiology, clinical response, and ability to obtain source
control (BPS)
Source control Remove intravascular access devices if confirmed to be source of sepsis after alternative access is obtained
Emergently achieve source control if possible (BPS)
Fluid therapy If intensive care support is available, administer up to 40–60mL/kg in bolus fluids during the first hour andmonitor for
signs of fluid overload
If intensive care support therapies are unavailable,
b
administer bolus fluids only in the presence of hypotension
Avoid starches (hydroxyethyl starch) or gelatin in acute resuscitation
Hemodynamicmonitoring Use advanced hemodynamicmonitoring, if available, in addition to bedside clinical variables to guide resuscitation
Use trends in blood lactate levels to guide resuscitation
Respiratory support therapy Consider a trial of non-invasivemechanical ventilation in children responding to resuscitationwithout clear indication
for intubation (weak). No recommendation regarding intubation in childrenwith fluid or catecholamine-resistant
septic shock
FollowARDS treatment recommendations including prone positioning, neuromuscular blockage, and high PEEP, do
not routinely use iNO
Endocrine andmetabolic Do not use IV hydrocortisone in childrenwith septic shock responding to fluids and/or vasopressor therapy. No
recommendation regarding the use of IV hydrocortisone in refractory shock
Do not use insulin to target lower blood glucose levels
Consider early enteral nutrition
Note. Adapted fromWeiss et al.17
Abbreviations: ARDS, acute respiratory distress syndrome; BPS, best practice statements; iNO, inhaled nitric oxide; IV, intravenous; PEEP, positive end-
expiratory pressure.
aWeak recommendation, very low-quality evidence.
bInmostUS settings, intensive care support therapies such as inotropes or ventilation can, at least temporarily, be administered in the emergency department
andward environments even in facilities with no on-site ICU; this recommendation is indicated for settings where no such support can be provided.
ity associated with aggressive fluid administration. At present, the
only high-grade evidence relates to the Fluid expansion as support-
ive therapy (FEAST) study,73 which observed substantially higher
mortality in children in Africa with infection and organ dysfunction
receiving fluid boluses. The challenge in ascertaining the relevance
of these findings for high-income settings where critical care support
to deal with the side effects of fluid overload (such as respiratory
failure) remains. The SSC panel therefore made a recommendation
that takes the health care setting into account. In settings where
intensive care interventions such as ventilation and inotropes can
be provided (which is the case, at least currently, for most EDs in
the United States), 40–60 mL/kg isotonic fluid boluses should be
administered during the first hour in increments of 10–20 mL/kg.
Fluid administration needs to be titrated to signs of perfusion and
organ dysfunction and should be discontinued if signs of fluid overload
develop. In contrast, in settings where intensive care is not available,
fluid resuscitation should be restricted to children with hypotension
using more judicious fluid amounts of 10–20 mL/kg during the first
hour.
Normal saline, lactated Ringer’s, and to a lesser extent PlasmaLyte
are the most commonly used isotonic fluids in pediatric sepsis. The
administration of normal saline results in a hyperchloremic metabolic
acidosis that can exacerbate the acidosis already common in sepsis
and has been associated with decreased renal perfusion and increases
in morbidity.74–76 Balanced fluids have been demonstrated to reduce
acute andpersistent kidney injury andmortality in adultswith sepsis.77
For these reasons, the new pediatric SSC recommendations suggest
using balanced fluids for initial resuscitation, acknowledging that
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TABLE 8 Empiric antimicrobial coverage in children with sepsis
a
Group Regimen Notes
Previously healthy Third-generation cephalosporin+ vancomycin Can use cephalosporinmonotherapy in regions with
minimalMRSA or resistant pneumococci; consider
adding an aminoglycoside in regions with substantial
ceftriaxone resistance amongGram-negative
organisms
Immunocompromise Vancomycin+ anti-pseudomonal cephalosporin (eg,
cefepime) or extended-range PCN/Beta-lactamase
combination (eg, piperacillin-tazobactam) or a
broad-spectrum carbapenem (eg, meropenem)
Vancomycin and cefepime has been associatedwith




Vancomycin+ anti-pseudomonal cephalosporin (eg,
cefepime) or extended-range PCN/Beta-lactamase
combination (eg, piperacillin-tazobactam) or a
broad-spectrum carbapenem (eg, meropenem)
Recognize predominance of Gram-negative enterics in
TPN-dependent childrenwith intestinal failure and
risk of pseudomonal sepsis in febrile neutropenic
children




Vancomycin AddGram-negative coverage if immunocompromise or





Vancomycin+ (piperacillin/tazobactam or cefepime or
ceftazidime or carbapenem)
If high risk of mortality or recent receipt of
broad-spectrum antibiotics, consider administration
of 2 antibiotics with Gram-negative coverage, trying
to avoid giving 2 beta-lactam agents together (for




Extended-range PCN/Beta-lactamase combination or
carbapenem, or addition of metronidazole or
clindamycin
Requires more robust anaerobic coverage (eg,
piperacillin-tazobactam)
Influenza-like illness Oseltamivir, peramivir, or other influenza treatment;
consider Gram-positive coverage
Biphasic illness with influenza concerning for bacterial




Addition of clindamycin or lincomycin Limits toxin production
Necrotizing fasciitis
c
Vancomycin+ piperacillin/tazobactam (or vancomycin
+ carbapenem); alternative: ceftriaxone+
metronidazole
PCN+ clindamycin for group A Streptococcus
(Streptococcus pyogenes)
Travel history Consider treatment for malaria or rickettsial diseases
Abbreviations: AKI, acute kidney injury; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PCN, peni-
cillin; TPN, total parenteral nutrition.
aVariables to consider in the selectionof antimicrobial agents include local epidemiology andantibiotic resistancepatterns, a child’s prior cultures, risk factors
for specific infections, and potential drug toxicities.
bIncludes septic arthritis, osteomyelitis, or pyomyositis.
cRole for early surgical intervention for source control and to obtain culture data to facilitate targeted antibiotic coverage.
further pediatric data are needed to ascertain the optimal fluid for
resuscitation of children with sepsis.78 The group recommended
against the administration of blood products for non-bleeding chil-
dren who were not anemic (hemoglobin ≥7 g/dL), as data do not
support empiric administration of packed RBCs, platelets, or plasma in
improving outcomes in this group.
Epinephrine or norepinephrine are recommended as first-line vaso-
pressors over dopamine for fluid-refractory sepsis, with insufficient
data to recommend either one specifically. Vasopressor administration
initially can be through either peripheral intravenous, intraosseous, or
central venous catheter (CVC). Limited data existed to suggest maxi-
mum rates to administer peripherally. Vascular access should not delay
inotrope administration. The decision to place a CVC in the ED using
point-of-care ultrasound should be made in conjunction with ICU col-
leagues, depending on the expertise of the ED healthcare workers in
the placement of CVCs, risk of infection in a CVC placed under poten-
tially suboptimal conditions of sterility, clinical stability of the child,
and how long the child is anticipated to remain in the ED. Trending
lactate levels can be used to guide resuscitation. Hydrocortisone can
be considered for fluid-refractory and vasopressor-refractory shock,
but there is no recommendation to administer intravenous hydro-
cortisone in the new guidelines. Finally, extracorporeal membrane
oxygenation (ECMO) remains an option for children in septic shock
refractory to conventional support, acknowledging that ECMO is only
available at specialized centers and optimal patient selection remains
challenging.79
The previous ACCCM recommendations31 differentiated between
warm shock (bounding pulses, flash capillary refill, warm extremity
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temperatures, wide pulse pressure) versus for cold shock (thready
pulse, slow capillary refill, cold extremities, narrow pulse pressure,
mottled appearance) to select vasoconstrictors versus inotropes.How-
ever, vital signs and clinical evaluation poorly differentiate between
cold and warm shock and inaccurately identify children with cardiac
dysfunction.80 Therefore, the new pediatric SSC guidelines recom-
mended against the use of clinical parameters to categorize children
as being in warm versus cold shock. Advanced hemodynamic monitor-
ing (eg, arterial blood pressures, central venous oxygen saturations) in
addition to clinical assessment may provide more reliable guidance in
relation to systemic vascular resistance, filling, and cardiac output, but
is operator dependent and often unavailable in the ED.
5.4 Near-infrared spectroscopy
The microcirculatory changes of sepsis precede diversion of blood
from end-organs and cannot necessarily be predicted from macro-
hemodynamic values such as vital signs. Detecting these early micro-
circulatory changes could lead to earlier diagnosis and improved
outcomes81; however,microcirculation is difficult tomonitor.Microcir-
culatory tests such as lactic acid, acid-base status, and central venous
oxygen saturation levels are invasive, not always available, and do not
offer the advantage of continuousmonitoring.
Near-infrared spectroscopy (NIRS) is a non-invasive, real-time,
easily applied tool that continuously monitors microcirculation and
regional tissue oxygen saturation (StO2) without requiring a pulsatile
signal. NIRS uses the absorption of infrared light emitted from a probe
that passes through skin or bone into underlying tissue, giving a venous
weighted hemoglobin saturation in tissue.82 NIRS-derived cerebral
StO2 correlates with central venous oxygen saturation.83–86 Abnor-
mal NIRS values have been shown to identify perfusion deficits earlier
than lactate or base deficit.87 A systematic review and meta-analysis
of adults showed that patients with severe sepsis or septic shock have
lower levels of StO2 with survivors having higher levels of StO2 com-
pared with non-survivors.88 However, the utility of StO2 in pediatric
sepsis has not been well studied. The potential for StO2 as a resuscita-
tion target in sepsis and incorporation into a risk score alongwith other
predictor variables are possible avenues for future investigation.
5.5 Respiratory support
Many children will respond to initial sepsis therapy. If signs of res-
piratory distress of failure develop, a trial of non-invasive positive-
pressure ventilation can be considered for children who lack clear
indications for intubation.17 Although the guidelines do not specifi-
cally recommend airway management, intubation should be consid-
ered for children with fluid-refractory and catecholamine-refractory
shock. Etomidate as an induction agent should be avoided, as small
studies have found significant adrenal suppression in adults with sep-
sis intubated with etomidate as opposed to other agents.89 Although
there are limited data on optimal induction agents for children, the use
TABLE 9 Risk factors for mortality in pediatric sepsis in
high-resource settings
Category Risk factor
Demographic Age< 1 year















Abbreviations: AKI, acute kidney injury; ECMO, extracorporeal membrane
oxygenation.
of ketamine or fentanyl (the latter potentially administered at lower
doses in children with hypotension) may facilitate intubation without
causing adrenal suppression. Once intubated, children with acute res-
piratory distress syndrome and sepsis may require higher (>10 cm
H2O) positive end-expiratory pressure to prevent alveolar collapse
and optimize oxygenation, and best practices for pediatric acute res-
piratory distress syndrome including prone positioning and consider-
ation for ECMO in cases of refractory respiratory failure should be
followed.79
6 OUTCOMES
Recent studies from high-income countries indicate that ≈3%–7% of
childrenwith sepsis presenting to EDsdie,withmortality rates increas-
ing to up to 20% for those with septic shock treated in PICUs.1,9,90
In resource-limited settings, mortality rates as high as 50% remain
a daily reality.4 The majority of pediatric sepsis deaths occur within
48 hours of presentation, and specific risk factors for mortality have
been identified (Table 9).10,11,91–93 Early deaths are usually attributed
to refractory shock, whereas late deaths are more often associated
withmultiorgan system dysfunction.94
In recent years, the relevance of long-term outcomes beyond the
hospitalization of childrenwith sepsis received increasing attention.Of
concern, more than one-third of pediatric survivors had not regained
their baseline health-related quality of life one year after an episode of
community-acquired sepsis.95 Lower quality-of-life scores were asso-
ciated with multiorgan dysfunction, renal replacement therapy, ECMO
or cardiopulmonary resuscitation, and duration of mechanical ventila-
tion and inotropes.96 Similar findings were observed internationally.11
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Given that most children with sepsis are younger than 10 years of age,
the long-term impact of sepsis sequelae on children, their families, and
society cannot be emphasized enough.
7 CONCLUSIONS
Sepsis remains a leading cause of death in children in the United States
and globally, and its toll on short-term and long-term outcomes for this
vulnerable patient group is substantial. Yet the relative rarity of sepsis
in comparison to common febrile infections, combined with often non-
specific earlymanifestations, canmakeprompt recognition inEDs chal-
lenging. The use of clinical decision support and sepsis protocols have
been shown to reduce morbidity and mortality in children with sepsis
and should be implemented and audited as best practice to save lives
and improve outcomes for children with sepsis.
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